Anticoagulants

Product Code GIA00791
Publication Date September 2010
Publisher Global Industry Analysts
Product Type Report
Pages 487
ISBN Number not applicable
Change currency
PDF £2,845.00 €3,426 $4,499 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Anticoagulants

This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following segments :

  • Oral Anticoagulants
  • and Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin).

The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 51 companies including many key and niche players such as AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, Sanofi-Aventis. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Contents

  • 1.Introduction, Methodology & Product Definitions
    • Study Reliability and Reporting Limitations
    • Disclaimers
    • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
    • Product Definitions and Scope of Study
  • 2.Industry Overview
    • A Rapidly Evolving Market
    • Current and Future Analysis
    • Warfarins & Heparins: Dominating Anticoagulants Market
    • Table 1: Global Anticoagulants Market (2007): Percentage Share Breakdown of Prescriptions for Lovenox, Arixtra, Fragmin, and Innohep (Includes Corresponding Graph/Chart)
    • Oral Anticoagulants Market
    • Novel Oral Anticoagulants to Fuel Venous Thromboembolism Drug Market
    • Injectable Anticoagulants Market
    • Heparin Market
    • Lmwh Market
    • An Introduction to Thrombosis and Antithrombotic Drugs
    • A Snapshot of Available Therapies
    • An Insight into Currently Available Antithrombotic Drugs
    • Weaknesses of Available Therapies
  • 3.Market Dynamics
    • An Insight into The Pharmaceuticals Industry
    • Industry Framework
    • Regulatory Price Controls - Present and Future
    • Consolidations Driving The Industry
    • Patent Expiries Giving Way to Generic Drugs
    • Drug Advancements Drive Anticoagulant Market
    • Niche Markets – The New Target for Drug Makers
    • An Opportunity to Grow Further
    • Direct Thrombin Inhibitors
    • Factor Xa Inhibitors
    • Geriatric Patients – at High Risk of Blood Clots
    • Improved Anticoagulant Agents for Children Group
    • Growing Demand for Self-Testing
    • Lmwhs Eases Outpatient Management
    • Concern over Underutilization of Warfarin
    • Anticoagulants to Lose Ua/Ami Markets to Antiplatelets
    • Novel Heparins Enhance Market Potential
    • Anticoagulant Therapy during Pregnancy Improves Outcomes
    • New Therapies: Need of The Hour
    • Anticoagulant Therapy in Ipf: Reduces Mortality Risk
    • Failure of Exanta
  • 4.Product Overview
    • Introduction to Anticoagulants
    • Evolution of Anticoagulants
    • Blood Coagulation – A Major Concern
    • Anticoagulants Disrupts Metastatic Events
    • The Coagulation Cascade
    • Coagulation Factors Found in The Coagulation Cascade
    • Precautions
    • Side Effects
    • Hemorrhagic Symptoms and Side Effects
    • Impediments
    • Potential Candidates for Anticoagulation
    • Alternative Therapies to Anticoagulants
    • Thrombolytics – Another Major Solution for Thrombosis
    • Anticoagulants Drug Class
    • Oral Anticoagulants
    • Oral Anticoagulants Induces Calcification
    • Warfarin
    • Advantages and Alternatives
    • Side Effects
    • Limitations
    • Coumadin
    • Injectable Anticoagulants
    • Heparin – The Back Bone of Injectable Anticoagulants
    • Unfractionated Heparin
    • Advantages and Alternatives
    • Limitations
    • Low Molecular Weight Heparins
    • Costs
    • Impediments
    • Lovenox/Clexane (Enoxaparin)
    • Approved Indications for Lovenox:
    • Advantages and Alternatives
    • Fragmin (Dalteparin)
    • Approved Indications for Fragmin Use:
    • Contradictions
    • Precautions
    • Fraxiparine (Nadroparin)
    • Innohep (Tinzaparin)
    • Contraindications
    • Side Effects
    • Other Serious Adverse Events Associated with Innohep
    • Precautions
    • Normiflo (Ardeparin)
    • Clivarine (Reviparin)
    • Table 2: Summary of Available Lmwhs
    • Non-Heparin Injectables
    • Arixtra (Fondaparinux)
    • Contraindications
    • Market and Market Participants
    • Angiomax (Bivalirudin)
    • Advantages
    • Contraindications
    • Side Effects
    • Argatroban/Novastan
    • Side Effects
    • Precautions
    • Refludan (Lepirudin)
    • Orgaran (Danaparoid Sodium)
    • Contraindications
    • Side Effects
    • Caution
    • Precaution
    • A Comparative Analysis of Various Direct Thrombin Inhibitors
    • Other Anticoagulants
    • Lithium Heparin
    • Edta
    • Citrate
    • Oxalate
  • 5.A Comparative Study of Anticoagulant Therapies
    • A Comparative Study of Warfarin against Lmwhs
    • A Comparative Study of Lmwh against Ufh
    • A Comparative Study of Heparin against Angiomax
    • A Comparative Study of Arixtra against Ufh and Lmwh
    • A Comparative Study of Angiomax against Ufh and Lmwh
  • 6.Areas of Indication
    • Indications for Anticoagulant Use
    • Venous/Dvt Thrombosis Indications
    • Desired Anticoagulant Qualities for Dvt Indications
    • Venous Thromboembolism
    • Deep Vein Thrombosis
    • Pulmonary Embolism
    • Orthopedic (Hip or Knee Replacement) Surgery
    • General Surgery
    • Cancer
    • Arterial Thrombosis Indications
    • Arterial Thrombosis
    • Acute Coronary Syndromes
    • Atrial Fibrillation
    • Unstable Angina
    • List of Approved Anticoagulants for Unstable Angina
    • Myocardial Infraction
    • Non St-Segment Elevation Mi
    • List of Approved Anticoagulants for Non-St Segment Elevation Myocardial Infarction
    • Percutaneous Transluminal Coronary Angioplasty (Ptca)
    • List of Approved Anticoagulants for Angioplasty Procedures
    • Heparin Induced Thrombocytopenia (Hit) Indications
    • Hit Type I
    • Hit Type Ii
    • Heparin Induced Thrombocytopenia with Thrombosis (Hitts)
    • Other Indications
    • Hemodialysis
  • 7.Drug Development Pipeline
    • Select Anticoagulants under Pipeline
    • Idraparinux – Sanofi-Aventis
  • 0673 – Sanofi-Aventis
    • Bibr1048ms - Boehringer Ingelheim
  • 8.Product Introductions/Approvals
    • Teva Receives Fda's Tentative Approval for Argatroban
    • Trimgen Receives Fda 510(K) Approval for Marketing Eq- Pcr™ Lc Warfarin Genotyping Kit
    • Lundbeck Launches Atryn® Commercially in The US
    • The Medicines Co Receives European Approval for Angiox (Bivalirudin)
  • 9.Product Introductions/Innovations in Recent past – A Perspective Builder
    • Bayer's Xarelto Receives Approval in Canada and Eu
    • Boehringer Receives Eu Approval for Pradaxa
    • Sanofi-Aventis Receives Approval for Clexane® in Japan
    • Paragondx Receives US Fda Approval for Its Rapid Genotyping Assay
    • Lannett Obtains US Fda Approval for Dipyridamole Tablets
    • Kimball Introduces New Pharmacogenetic Test
    • Roche Launches An Improved Point-of-Care Anticoagulation Monitoring System
    • Danish Agency Grants Approval for Anticoagulant Clinical Trials
    • Emea Approves Arixtra® of Glaxosmithkline
    • Fda Approves Andas of Pliva
    • Fda Approves Arixtra Injection of Gsk
    • Japanese Ministry Approves Arixtra of Gsk
    • Eisai Obtains Fda Approval for Fragmin
    • Sanofi-Aventis' Lovenox® Obtains Fda Approval for Acute Cardiac Care
    • Zydus Cadila's Warfarin Secures Approval from US Fda
  • 10.Recent Industry Activity
    • Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim
    • Portola Inks $470 M Agreement with Merck for Phase Ii Anticoagulant
    • Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma
    • Nuvelo and Arca Biopharma Merge
  • 11.Corporate Activity in Recent past – A Perspective Builder
    • Teva Acquires Barr Pharmaceuticals
    • Meda Ab Acquires Marcoumar Anticoagulant Brand from Roche
    • Gtc Biotherapeutics Finalizes Collaboration Deal with Ovation for Atryn®
    • Diakron Licenses Oral Anticoagulant Compound from Merck
    • Trinity Biotech to Distribute Abi's Hpf4 Assay in Germany and The US
    • Orchid to Develop & Manufacture New Anticoagulant Drug Compound from Merck
    • Paion Acquires Cenes Pharmaceuticals
    • Paion Announces Acquisition of Global Rights to Trigen's Flovagatran
    • Biological E Collaborates with Choncept and Heparinex
    • Bayer's Market Expansion
    • B. Braun Recalls Heparin Sodium Based Injection Solutions
    • Baxter Recalls Heparin Sodium Vials
    • Celgene Acquires Pharmion
    • Bms Collaborates with Pfizer
    • Medicines Company Reacquires European Rights for Angiox
    • Hemosense and Labcorp Sign Agreement for Supply of Inratio System
    • Sanofi-Aventis Acquires Rights for Panaldine from Daiichi
    • Alchemia Inks Marketing Alliance with Dr Reddy's for Heparin
    • Inverness Announces Acquisition of Hemosense
    • Ev3, Foxhollow Complete Merger
    • Osmetech Signs Licensing Agreement with Marshfield Clinic
    • Mitsubishi and Tanabe Agree to Merge
    • Artisan and A-Bio Form Alliance
    • Archemix and Nuvelo Announces Expansion of Alliance
    • American Capital Acquires Scientific Protein Laboratories' One Stop Buyout™
    • Bristol-Myers to Start New Facility in Massachusetts
    • Astrazeneca Stops Development of Exanta
    • Pfizer Enters into Agreement with Bpc
  • 12.Focus on Select Global Players
    • Astrazeneca Plc (UK)
    • Bristol-Myers Squibb Company (USA)
    • Glaxosmithkline Plc (UK)
    • Leo Pharmaceutical Products (Denmark)
    • Mitsubishi Tanabe Pharma Corporation (Japan)
    • Pfizer Inc. (USA)
    • Sanofi-Aventis (France)
    • Teva Pharmaceutical Industries Ltd (Israel)
    • Teva Pharmaceuticals USA (US)
  • 13.Global Market Perspective
    • Table 3: World Recent past, Current & Future Analysis for Anticoagulants by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 Includes Corresponding Graph/Chart)
    • Table 4: World Historic Review for Anticoagulants by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 5: World 11-Year Perspective for Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
    • Table 6: World Recent past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 7: World Historic Review for Oral Anticoagulants by Geographic Region/ Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 8: World 11-Year Perspective for Oral Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
    • Table 9: World Recent past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 10: World Historic Review for Injectable Anticoagulants by Geographic Region/ Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 11: World 11-Year Perspective for Injectable Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
    • Table 12: World Recent past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 13: World Historic Review for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 14: World 11-Year Perspective for Injectable Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed for Years 2005, 2010 & 2015
    • Table 15: World Recent past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 16: World Historic Review for Unfractionated Heparin by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 17: World 11-Year Perspective for Unfractionated Heparin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart
    • Table 18: World Recent past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 19: World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 20: World 11-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 14.The United States
    • A. Market Analysis
    • Outlook
    • Atrial Fibrillation – A Key Risk Factor
    • Regulatory Route to The US Market
    • Price Controls
    • US Anticoagulants Market
    • US Heparin Market
    • Hinging on Market Opportunities
    • Generics – Threatening Branded Anticoagulants
    • List of Patent Protected Anticoagulants in The US
    • Ignorance – A Major Hindrance
    • Future Challenges and Growth Drivers
    • US Emerging Anticoagulant Market
    • US Emerging Anticoagulants Market: Select Products in The Pipeline
    • B. Market Analytics
    • Table 21: US Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 22: US Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 23: US 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 15.Japan
    • A. Market Analysis
    • Outlook
    • Anticoagulants Market in Japan
    • Rising Incidence of Pulmonary Thromboembolism
    • B. Market Analytics
    • Table 24: Japanese Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 25: Japanese Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 26: Japanese 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16.Europe
    • A. Market Analysis
    • Outlook
    • Anticoagulants Market in Europe
    • List of Patent Protected Anticoagulants in Europe
    • Market in High Need of An Ideal Therapy
    • B. Market Analytics
    • Table 27: European Recent past, Current & Future Analysis for Anticoagulants by Geographic Region/Country – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 28: European Historic Review for Anticoagulants by Geographic Region / Country – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 29: European 11-Year Perspective for Anticoagulants by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
    • Table 30: European Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 31: European Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 32: European 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16a.France
    • Market Analysis
    • Table 33: French Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 34: French Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 35: French 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16b.Germany
    • A. Market Analysis
    • Outlook
    • Market Drivers for Injectable Anticoagulants
    • Anticoagulants Growth Drive European Poc Testing Market
    • B. Market Analytics
    • Table 36: German Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 37: German Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 38: German 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16c.Italy
    • Market Analysis
    • Table 39: Italian Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 40: Italian Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 41: Italian 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16d.The United Kingdom
    • A. Market Analysis
    • Outlook
    • Growing Af Market for Warfarin
    • B. Market Analytics
    • Table 42: UK Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 43: UK Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 44: UK 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16e.Spain
    • Market Analysis
    • Table 45: Spanish Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 46: Spanish Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 47: Spanish 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 16f.Rest of Europe
    • Market Analysis
    • Table 48: Rest of Europe Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 49: Rest of Europe Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 50: Rest of Europe 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • 17.Rest of World
    • A. Market Analysis
    • Outlook
    • Anticoagulants Market in Australia
    • B. Market Analytics
    • Table 51: Rest of World Recent past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (Includes Corresponding Graph/Chart)
    • Table 52: Rest of World Historic Review for Anticoagulants by Product Segment – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (Includes Corresponding Graph/Chart)
    • Table 53: Rest of World 11-Year Perspective for Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for The Years 2005, 2010 & 2015 (Includes Corresponding Graph/Chart)
  • Total Companies Profiled: 51 (Including Divisions/Subsidiaries - 56)
  • Region/Countryplayers
    • The United States
    • Canada
    • Japan
    • Europe
    • France
    • Germany
    • The United Kingdom
    • Rest of Europe
    • Asia-Pacific (Excluding Japan)
    • Latin America
    • Middle-East